The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by The Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium).
The partnership’s goal is to accelerate the development of novel 4R tau and alpha-synuclein PET tracers for primary non-Alzheimer’s tauopathies, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and other neurodegenerative diseases. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders.
Applications should focus on studies that achieve one or more of the following:
- In vivo imaging of brain neurofilaments of 4R tau and alpha-synuclein pathology that could be useful as biomarkers of the presence of disease and disease progression and as pharmacodynamic tools for drug development for tauopathies or synucleinopathies
- Structure- and ligand-based drug design approaches that use state-of-art computational methods based on the high resolution Cryo-EM structures of disease-relevant tau and alpha-synuclein fibrils and existing Structure Activity Relationship (SAR) on known tau PET ligands or alpha-synuclein PET ligands that are in development
We are especially interested in projects to develop alpha-synuclein and tau tracers in parallel.
Watch our informational webinar on-demand to learn more about our Foundation's funding strategy and opportunities, and the application and review processes. Watch Now.
Please note we made changes to our publication and indirect costs policies in early 2020. Review the updated Application Guidelines and the new open access publication policy for complete details. Contact email@example.com with questions about the RFA, application process, or these policies.